Dr. Colin Rowlings is a member of Quotient Sciences' Scientific Advisory Board.

Dr. Rowlings is a seasoned pharmaceutical executive with over 35 years of experience in small-molecule drug development. He has led CMC organizations at Actio Biosciences, Gossamer Bio, and Ardea Biosciences, and has contributed to the development of oral, inhalation, nasal, and parenteral dosage forms, including enabling technologies such as ASDs and modified-release formulations.

Dr. Rowlings has also supported over 30 biotech companies as an independent consultant and served as an expert witness in patent litigation. He has taught at the UCSD School of Pharmacy since 2007.

Dr. Rowlings earned his B.Pharm. in Pharmacy from the University of Queensland, Australia and Ph.D. in Pharmaceutics from the University of Iowa.